Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from the China Securities Regulatory Commission to issue new domestic shares to a specific subscriber. This approval allows the company to proceed with the subscription under the specific mandate, marking a significant step in their financial strategy. The issuance will be conducted in accordance with regulatory requirements within the next 12 months.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.